Publication: Role of endothelin in obstructive jaundice
| dc.contributor.authors | Sarac, A. M.; Aktan, A. O.; Moini, H.; Bilsel, S.; Scapa, E. | |
| dc.date.accessioned | 2022-03-15T11:23:30Z | |
| dc.date.accessioned | 2026-01-11T09:17:39Z | |
| dc.date.available | 2022-03-15T11:23:30Z | |
| dc.date.issued | 1999 | |
| dc.description.abstract | Mediators responsible for renal changes in obstructive jaundice are not specified. This study is designed to study the role of endothelin-1 (ET-1) in obstructive jaundice in rats. Animals were randomly placed into five experimental groups. Group 1 (N = 3) was the sham-operated group. Group 2 (N = 8) after common bile duct (CBD) ligation, received bosentan, which is a nonselective endothelin receptor blocker, 50 mg/kg/day for seven days. Group 3 (N = 7) received 1 microg/kg/day captopril. Group 4 (N = 7) was given both drugs orally for seven days. Group 5 (N = 6) after CBD ligation, received Arabic gum as the vehicle. Blood was drawn from the infrahepatic vena cava for the determination of ET-1, bilirubin, creatinine, protein oxidation products, hyaluronic acid, and beta-N-acetyl-hexosaminase. Liver tissue samples were obtained to determine glutathione levels. ET-1, protein oxidation products, hyaluronic acid, bilirubin, and creatinine levels increased significantly in the control group when compared with sham. Bosentan effectively prevented ET-1 elevation but could not reverse creatinine or bilirubin elevation. Captopril with or without bosentan was cytoprotective but did not reverse increased creatinine levels. It is concluded that increased ET-1 in obstructive jaundice may be one of the contributing factors of renal damage. | |
| dc.identifier.doi | 10.1023/a:1026614803584 | |
| dc.identifier.issn | 0163-2116 | |
| dc.identifier.pubmed | PMID: 10063923 | |
| dc.identifier.uri | https://hdl.handle.net/11424/249984 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | Digestive Diseases and Sciences | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | Animals | |
| dc.subject | Male | |
| dc.subject | Rats | |
| dc.subject | Random Allocation | |
| dc.subject | Liver | |
| dc.subject | Kidney Diseases | |
| dc.subject | Creatinine | |
| dc.subject | Rats, Sprague-Dawley | |
| dc.subject | Cholestasis | |
| dc.subject | Captopril | |
| dc.subject | Bosentan | |
| dc.subject | Endothelin Receptor Antagonists | |
| dc.subject | Sulfonamides | |
| dc.subject | Hyaluronic Acid | |
| dc.subject | Angiotensin-Converting Enzyme Inhibitors | |
| dc.subject | Bilirubin | |
| dc.subject | Endothelin-1 | |
| dc.subject | beta-N-Acetylhexosaminidases | |
| dc.title | Role of endothelin in obstructive jaundice | |
| dc.type | article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 363 | |
| oaire.citation.startPage | 356 | |
| oaire.citation.title | Digestive Diseases and Sciences | |
| oaire.citation.volume | 2 |
